Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 10k
28 January 2020
Question for written answer E-000480/2020
to the Commission
Rule 138
Pascal Arimont (PPE)
 Answer in writing 
 Subject: Fair and transparent prices for pharmaceuticals

In a position paper (1) , AIM (Association of Mutual Benefit Societies), the umbrella organisation representing mutual benefit societies in the health sector and health insurance funds, criticises the opaque nature of the pricing system for pharmaceuticals. The cost of cancer treatment, which the paper claims increased tenfold between 1995 and 2010, is cited as one example. AIM calls for greater transparency, in order to ensure that fair prices are set for medicines and make medicines affordable for everyone. It also criticises the failure on the part of pharmaceutical companies to invest sufficiently in key areas. New approaches are needed to make innovative medicines more readily available. AIM proposes, for example, a European model for calculating fair prices which takes account of investment in research and development. It also calls on the Commission to set up a high-level working party on a fair pricing policy on which all stakeholders are represented.

Has the Commission noted the proposals made in AIM’s position paper and does it plan to put them into practice?

Original language of question: DE
Last updated: 25 September 2020Legal notice - Privacy policy